Baseline Expression Levels of WNT8B, KRT2, and TTLL13P are associated with abrocitinib response in atopic dermatitis
Published: 15 October 2025| Version 1 | DOI: 10.17632/g6hvm2znjn.1
Contributors:
Yuwen Gao, Yang Luo, Yingxia Gao, Xingyu Chen, Yu Zhang, Yuan Zhou, Beilei Xu, Xu Yao, Xiaochun LiuDescription
Our real-world data from 96 patients confirms that abrocitinib induces rapid clinical improvement and broadly downregulates genes in cytokine and JAK-STAT signaling pathways. We also identified that patients achieving EASI-90 response had a distinct baseline profile characterized by lower Th2 cytokines and a specific transcriptomic signature of high WNT8B and low TTLL13p and KRT2 expression. This signature was validated as a predictive biomarker in an independent cohort, suggesting it can be used to stratify patients for a higher likelihood of achieving minimal disease activity with abrocitinib.
Files
Institutions
Chinese Academy of Medical Sciences and Peking Union Medical College
Categories
Dermatology, Atopic Dermatitis, Dermatitis, Eczema
Funding
Pfizer Health Research Foundation
78229835
National Natural Science Foundation of China
82373489，82330098, 82273542, 82103735, 82304023, 82404151